Datasets:
Javtor
/
biomedical-topic-categorization-validation

Dataset card Data Studio Files
xet
Community
PMID
int64
35.7M
36.4M
Title/Abstract
stringlengths
22
8.78k
MeshTerms
stringlengths
7
101
SemanticTypes
stringlengths
4
64
36,281,933
coptisin attenu postinfecti ib via nrfdepend inhibit nlpr inflammasom inhibit activ nlr famili pyrin domaincontain nlrp inflammasom previous report confer protect postinfecti irrit bowel syndrom piib coptisin second abund isoquinolin alkaloid copti chinensi inhibit nlrp inflammasom activ howev whether coptisin exhibit protect effect piib remain unclear present studi coptisin signific reduc gastrointestin motil abdomin withdraw reflex score piib rat model induc use intragastr administr trichinella spirali larva coptisin treatment signific decreas protein level oxid stress marker hydroxynonen protein carbonyl hydroxydeoxyguanosin proinflammatori cytokin tnf il il colon piib rat moreov coptisin treatment signific increas nuclear factor erythroid relat factor nrf nuclear transloc heme oxygenas protein express level signific downregul protein express level nlrp apoptosisassoci specklik protein contain card caspas colon piib rat import note antiinflammatori effect coptisin block nrf inhibitor ml summari present studi indic coptisin potenti attenu piib rat via nrfdepend inhibit nlpr inflammasom
D058847;D043183
T123;T047;T116
36,281,932
exosom stat deriv high phosphorusstimul vascular endotheli cell induc vascular smooth muscl cell calcif via wntcatenin signal pathway vascular calcif common observ chronic kidney diseas mechan calcif signal endotheli cell transmit vascular smooth muscl cell vsmcs remain unknown aim present studi investig whether exosom huvec huvecexo could regul vsmc calcif potenti signal pathway huvecexo isol huvec phosphorus np high phosphorus hp condit alizarin red stain calcium ca content analysi carri detect calcif vsmcs proteom analysi carri detect differenti express exosom protein protein mrna level measur western blot analysi revers transcriptionquantit pcr rtqpcr exosom deriv hphuvec promot calcif vsmcs assess alizarin red stain alkalin phosphatas activ assay ca content measur increas express runtrel transcript factor osteopontin proteom analysi detect upregul stat hpexosom huvec huvecexo compar nphuvecexo also confirm western blot analysi rtqpcr inhibit stat express vsmcs use fludarabin knockdown stat express use small interf rna allevi calcif vsmcs furthermor lithium chlorid wnt activ revers protect effect stat inhibit vsmc calcif dickkopf wnt inhibitor exert opposit effect suggest activ wntcatenin signal pathway involv statmedi vsmc calcif conclus present result indic exosom stat deriv hptreat huvec could promot vsmc calcif activ wntcatenin pathway may potenti mechan vsmc calcif promot exosom
D009131;D061205
T047;T024
36,281,931
visual inspect reveal novel pathogen mutat pkd miss variant caller wholeexom sequenc autosom domin polycyst kidney diseas adpkd common type inherit cystic kidney diseas feasibl wholeexom sequenc wes obtain molecular diagnosi adpkd still question previous studi show conflict result util wes patient adpkd standard bioinformat pipelin demonstr pathogen variant gene interest visual read align use integr genom viewer region atyp align numer softclip read exon polycystin transient receptor potenti channel interact pkd gene demonstr total four visual inspect step outlin assess origin softclip read strand bias captur poor map sequenc error dna templat contamin follow assess atyp align pkd hypothes caus insertiondelet mutat sanger sequenc confirm presenc novel bp insert pkd nm cinstccccgcagtcttccccgca pvalleufst introduc prematur stop codon predict pathogen present studi demonstr wes could util molecular diagnost tool adpkd furthermor visual inspect read align key identifi pathogen variant propos visual inspect step may incorpor typic wes data analysi workflow improv diagnost yield
D016891
T019;T047
36,281,924
role glucos metabol ocular angiogenesi review glucos metabol major sourc energi play crucial role physiolog cell function mainten homeostasi glucos act predomin sourc metabol fuel generat atp involv biosynthesi epigenet thus glucos metabol maintain key role cell function homeostasi energi generat biosynthesi epigenet increas number studi reveal glucos metabol intric involv angiogenesi disrupt angiogenesi contribut sever vascular diseas ocular vascular diseas common ophthalmolog disord preval disord increas annual ocular vascular diseas larg occur abnorm congenit develop acquir disturb vasculatur thus identifi process occurr develop physiolog patholog angiogenesi utmost import involv understand insepar role intercellular communic vascular cell although vascular endotheli growth factor vegf wellrecogn therapeut target manag ocular vascular diseas vegfbas therapi fail achiev desir therapeut effect sever case part due drug resist noncompli present review current knowledg process role glucos metabol govern physiolog patholog ocular angiogenesi summar highlight vascular glucos metabol promis strategi maintain restor physiolog function vasculatur thus potenti amelior ocular vascular diseas
D042461;D014652
T123;T047;T116
36,281,920
calciumdepend activ phex mepe dmp osteocyt calcium ca signal first messeng signal exhibit osteocyt present studi aim better understand link ca concentr level bone miner regul protein phosphateregul neutral endopeptidas chromosom x phex matrix extracellular phosphoglycoprotein mepe dentin matrix protein dmp level oxid stress osteocyt viabil mloy cell determin use livedead assay follow treatment various ca concentr mm differ durat min h superoxid dismutas sod catalas cat glutathion gsh nadph oxidas nox enzym analyz use colorimetr method apoptosi detect caspas analysi furthermor protein express level phex mepe dmp analyz use immunoblot oxid stress examin use total antioxid total oxid status tos assay notabl min live cell dead cell howev min number dead cell increas follow treatment mm ca h dead cell live cell follow treatment mm ca h ca treatment highest protein express level phex mepe dmp measur cell treat mm ca addit ca concentr increas tos oxid stress index valu also increas conclus result suggest mm ca may trigger bone miner protein phex mepe dmp could consid applic dosag treatment bone damag futur
D010011;D053402
T116;T126;T025
36,281,919
long noncod rnas microrna regul stress cancer review resist stress featur cancer cell cellular stress includ oxid metabol genotox stress condit normal condit lead cell death howev contrast normal cell cancer cell overcom checkpoint normal restrict growth abl resist cellular stress subsequ cell death varieti mechan includ sever noncod rnas ncrnas within context long ncrnas lncrnas microrna mirnasmir main categori ncrnas shown literatur function regul stress resist pathway cancer mirna play key role major biolog pathway regul express hundr target gene includ gene involv stress respons cell death oncogen tumor suppressor gene inhibit protein translat promot degrad mrnas respect lncrnas epigenet regul also involv cancer progress stress respons metabol pathway promot inhibit transcript splice translat modul protein function thus present review summar recent knowledg relat role molecul cancer respons stress highlight abil noncod molecul effect drug target biomark cancer treatment
D062085;D035683;D009369
T123;T191;T114
36,281,918
singl site fe n c atom base carbon nanotub mutual promot synergist oncotherapi carbon nanotub cnt support singl site fe n c catalyst cntsfe n c exhibit attract properti peroxidas pod like activ phototherm effect herein design therapeut platform wrap doxorubicin dox mesopor cntsfe n c cell membran cm breast cancer ultim nanoag cntsfe n cdoxcm exhibit high antitumor activ account effici catalyt abil increas drug releas rate signific phototherm effect due pod like activ cntsfe n c could effect catalyz hydrogen peroxid h cytotox hydroxyl radic oh chemodynam therapi cdt tumor besid releas dox mere induc diagnosi tumor cell chemotherapi ct also generat h promot cdt moreov phototherm effect nanoag could use phototherm therapi ptt increas temperatur conduc releas dox micropor cell indirect enhanc ct cdt effect intellig multifunct drug deliveri platform present cntsfe n cdoxcm nanoag could engin synergist treatment favor biosafeti provid promis paradigm site specif antitumor treatment biomedicin
D037742;D001943;D009369;D053758
T104;T191;T073
36,281,914
acteosid allevi dextran sulphat sodiuminduc ulcer coliti via regul hohmgb signal pathway ulcer coliti uc signific burden human health elucid mechan develop potenti prevent treatment uc report acteosid act exhibit strong antiinflammatori activ present studi hypothes act may exert protect effect uc effect act inflamm oxid stress apoptosi evalu use dextran sulphat sodium dss treat mice dsstreat human colorect adenocarcinoma caco cell epitheli morpholog result demonstr acttreat mice dssinduc uc exhibit signific reduc colon inflamm demonstr revers bodi weight loss colon shorten diseas activ index score inflamm oxid stress colon barrier dysfunct vivo experi demonstr act inhibit dssinduc apoptosi colon tissu demonstr result tunel assay alter protein express level bax cleav caspas bcl furthermor dss signific stimul protein express level high mobil group box protein hmgb serv central role initi progress uc effect mark inhibit act final dss signific decreas protein express level heme oxygenas ho colon tissu effect act gsh apoptot protein hmgb mark attenu presenc ho inhibitor tin protoporphyrin conclus act amelior colon inflamm hmgb inhibit hodepend manner
D003093;D024243;D003092
T123;T047;T116
36,281,911
epiderm stem cell particip repair scald via nanog myc regul epiderm stem cell epsc high express regulatori factor nanog promot wound heal aim present studi investig effect mechan epiderm stem cell epsc heal scald under molecular mechan mous epsc isol skin tissu cultur vitro first prolif abil epsc determin via upregul downregul nanog express level epsc use mtsassay second wound heal assay epsc differ nanog express level perform investig cell migratori capac third protein express level various protein epsc nanog overexpress knockdown determin final transfect epsc appli rat scald model observ effect scald heal subsequ wound score reepitheli capillari densiti determin histolog result demonstr nanog overexpress enhanc prolif abil epsc via cellular c myc moreov lvnanog group epsc increas nanog express level exhibit improv heal abil wound heal test control group use western blot demonstr epsc transfect nanogoverexpress vector express high nanog protein express level wherea small interf rnananogtransfect epsc exhibit low nanog protein express level furthermor cmyc express synchron nanog express also reveal express level cmyc increas p express level also increas rat scald model nanogoverexpress epsc enhanc wound closur reepitheli epsc nanog knockdown exhibit opposit effect present studi therefor indic nanog may posit effect scald heal rat support use epscbas treatment scald furthermor suggest cmyc potenti serv key role process process avoid cancer reli supervis p
D016159;D002056
T123;T116;T037
36,281,901
effect sarcopenia serum myokin prognosi surviv cirrhot patient multicent cross section studi sarcopenia one signific contributor morbid patient chronic liver diseas serum myokin potenti biomark detect earli sarcopenia aim investig relationship serum myokin cirrhosi relat mortal earli stage diseas
D055948
T047
36,281,897
frame ration respons comment thought reward peer commentari target articl come broad rang disciplinari perspect engag commentari three group first discuss commentari appli basic approach new case consid target articl second explor help extend refin argument final offer repli object either overal framework specif argument
D013850
T078;T041
36,281,892
frame effect ration communic disinterest seem inconsist prefer predict languag pragmat inform non equival addit classic riski choic frame effect found asian diseas task risk avers gain risk seek loss appli gambl tend overgener non gambl situat
D012309;D005715
T055;T048
36,281,890
frame trade off perspect bermdez argu ration frame effect base normat appropri quasi cyclic prefer suggest argument conflat prefer specif outcom prefer outcom aspect instead impli quasi cyclic prefer frame affect decis standard econom trade off nonetheless demonstr frame affect behavior alter percept particular outcom aspect frame effect decompos
D003071
T041
36,281,889
self control modul inform salienc bermdez suggest agent use frame succeed self control commentari suggest frame effect steer behavior modul inform salienc analysi extend self control strategi beyond frame rais question whether remain explanatori role dual process theori self control
D000068356
T055
36,281,886
polyphoni principl bermdez ration frame effect consequ counterintuit phenomenon call normat polyphoni realiti singl action may logic consist sustain divers posit negat judgment show normat polyphoni emerg ontolog polyphoni divers possibl frame relev detail illustr polyphoni principl read dostoevski crime punish
D005197
T098
36,281,885
ration frame effect moral valid reason argu scope ration frame effect may broader bermdez assum even mani canon experi explan judgment revers shift may refer reason includ moral one refer asian diseas paradigm adp describ non consequentialist reason relat fair distinct allow may help explain justifi typic pattern choic case like adp
D009014;D007600
T078;T041
36,281,882
ceteri paribus prefer ration farm effect extension principl bermdez argu ration frame effect form quasi cyclic prefer suppos refut extension principl standard decis theori respons argu better analyz seem quasi cyclic prefer ceteri paribus prefer furthermor frame includ object choic acknowledg ration frame effect without reject extension
D000383
T090
36,281,878
frame motiv process frame group choic categori thus modifi incent effect make frame motiv choic rather neutral cognit particular frame inferior choic high short term payoff part broad categori choic recruit incent reject must motiv test case
D003071;D009042
T078;T041;T080
36,281,877
evolutionari role water access caviti src homolog sh domain protein excit state fundament understand biolog function despit fact hard observ use tradit biophys methodolog pressur perturb coupl nuclear magnet reson nmr spectroscopi power physicochem tool glanc low popul high energi state residu residu basi underpin mechanist insight protein function perform pressur titrat use nmr spectroscopi relax dispers experi identifi low lie energet state c abl sh domain show sh excit state contain hydrat hydrophob caviti fast exchang motion high conserv residu face water access hole discuss implic water protein interact sh modul achiev high affin bind promiscu phospho tyr peptid recognit
D018909;D014867
T087;T197;T121
36,281,875
bias suboptim choic anim suggest frame effect may ubiquit frame effect attribut quasi cyclic irrat complex human prefer ubiquit bias result simpler mechan found anim exampl frame effect vari simpl learn context analog human gambl behavior valu ad reinforc effort went obtain
D015982;D002755
T078;T055
36,281,874
four frame funer commentari bermdez much like bermdez analysi yet incomplet time problemat social decis make extens interperson conflict explain four frame gain loss oper conjunct human gravit toward loss frame without intervent lead breakdown cooper arguabl tragic funer common
D003220;D007398;D003657
T055;T041;T054;T080
36,281,872
distinguish self involv self serv choic frame effect distinguish two type case potenti generat quasi cyclic prefer self involv choic agent oscil first third person perspect conflict regard life chang implic self serv choic frame base reason first person ration yet third person irrat argu distinct type case deserv attent bermdez account
D011340
T041
36,281,871
studi ration frame effect need development psycholog experiment research review suggest ration frame effect influenc young children social activ accord logic interdepend howev young children unlik possess elabor cognit skill argu target articl prerequisit ration frame effect understand ration frame effect requir understand ontogenet origin
D066233;D012919
T091;T054
36,281,856
explain bias bias bermdez argu frame effect ration true one accept bias edit phase ration type ration call procedur simon despit procedur ration evalu phase frame effect stem bias way set refer point outcom compar
D015982
T078
36,281,855
ecolog benefit irrate moral trolley like dilemma case bermdez refer conscious quasi cyclic prefer dilemma ident outcom obtain moral non ident action argu moral context descript invari ecolog relev may crucial distinguish logic irrat moral choic short term may promot greater social benefit longer term
D009014
T078
36,281,854
frame equival ration infer bermdez case ration frame effect origin unconvinc give parenthet treatment problemat assumpt extension semant equival altern frame frame experi assumpt fals sometim valid infer frame effect follow neither infer human ration commentari recap central problem
D002755;D012660
T078;T055
36,281,853
refram ration exogen constraint control inform search bermdez argu frame effect ration particular frame provid goal consist reason choic peopl exert control frame decis problem propos instead observ rais question whether frame select ration process highlight constraint choic environ sever limit ration select frame
D003657;D002755
T055;T041
36,281,852
consist prefer conflict reason ration evalu bermdez argument favour ration quasi cyclic prefer conflat reason desir emot respons genuin prefer ration prefer format requir decis maker identifi reason also weigh coher way
D003657;D004644
T041
36,281,851
incomplet prefer ration frame effect normat principl descript invari presuppos ration prefer must complet complet axiom normat dubious howev reject open door ration frame effect commentari suggest bermdez insight challeng standard normat view frame clarifi extend situat within broader critiqu complet
D011340;D001525
T090;T055;T041
36,281,850
reput perspect ration frame effect assess whether behavior like frame effect ration research need consid decis maker goal argu research broaden scope analysi includ impress manag goal predict condit behavior tradit consid irrat eg loss gain frame effect risk prefer reput reward cast doubt strict claim irrate
D004644
T041
36,281,849
even simpl frame effect ration bermdez persuas argu frame effect irrat common suppos focus reason individu decis maker complex situat howev neglect crucial role social communic context elicit certain frame effect contend mani frame effect best explain term basic ration principl discours process pragmat reason
D003657;D002755
T055;T041
36,281,847
ration end thought bermdez convinc argu frame effect ubiquit sign human irrate unavoid featur intellig system commentari add frame effect aris even formal domain chess mathemat appear paradigm ration thought inde find attempt resolv clash differ frame major impetus delib cognit
D003071;D007360
T041
36,281,846
frame decis leak experienc decis connect bermdez argument previous theoriz leaki ration emphas decis process includ decis frame leak experi decis outcom suggest implic bermdez analysi broad applic studi virtual real world decis make field need substant formal theori ration
D003657;D034462
T054;T041
36,281,845
quasi cyclic prefer ethic plato aristotl kant bermdez describ extension principl almost unquest claim might come surpris philosoph work agenc ethic kantian deontolog ethic platon aristotelian virtu ethic prefer outcom ration affect outcom frame term maxim charact trait
D028663;D009014
T078
36,281,844
role phenylalaninetyrosin ammonia lyas anthocyanidin synthas enzym anthocyanin biosynthesi develop solanum melongena l genotyp solanum melongena wide consum veget crop compris health benefit phenol compound complex network biosynthet enzym involv synthes nutraceut includ anthocyanin present studi conduct investig activ key enzym involv biosynthesi accumul anthocyanin develop genotyp phenylalanin ammonia lyas pal tyrosin ammonia lyas tal anthocyanidin synthas an inadequ inform avail context fruit leaf tissu analyz enzym activ anthocyanin accumul studi includ character extract anthocyanin follow express studi gateway enzym an involv anthocyanin biosynthesi delphinidin major anthocyanidin present fruit tissu mg g melongena anthocyanin accumul back correl biochem analysi express studi studi shown variat pal tal an enzym differ tissu development stage enzym activ strong posit correl anthocyanin biosynthesi
D000872;D032323
T121;T168;T002;T109
36,281,843
quantif rosmarin acid differ plant speci lower himalayan region express analysi under l phenylalanin pathway studi adopt effect high perform liquid chromatographi hplc techniqu quantit determin rosmarin acid ra pcr base amplif biosynthet key regul isodon rugosus daphn mucronata viburnum grandiflorum lower himalayan region rosmarin acid engag varieti biolog process signific industri signific studi identifi crude methanol extract use thin layer chromatographi standard content quantifi use hplc without interrupt spike use mixtur methanol deioniz water contain acetonitril vv acet acid vv uv nm absorpt use rt pcr identifi cdnas encod pal ch ras imag j semi quantit analysi quantifi express level gene involv ra product chosen plant materi highest level pal ch ras detect band intens leav flower rugosus also exhibit substanti quantiti ra howev v grandiflorum mucronata transcript given gene low concentr ra rang mg g rugosus mg g v grandiflorum mg g mucronata studi demonstr method quantifi ra crude methanol extract effect indic rugosus might use indigen altern sourc ra
D000432;D010649
T121;T123;T116;T109;T131;T130
36,281,842
genet basi transpir sensit vapor pressur deficit wheat genet manipul whole plant transpir rate tr respons increas atmospher vapor pressur deficit vpd promis approach crop adapt various drought regim current futur climat genotyp non linear tr respons vpd expect achiev yield gain termin drought thank water conserv strategi linear respons exhibit consumpt strategi adequ well water transient drought environ wheat previous effort indic tr genet basi natur fluctuat condit tr respons variat temperatur photosynthet activ radiat evapor demand genet basi respons vpd per se never isol address develop control environ gravimetr phenotyp approach impos vpd regim independ confound environment variabl screen three nest associ map popul total line three time year period result dataset base phenotyp near plant enabl construct point respons curv genotyp subject genom wide associ studi analysi reveal hotspot tr respons vpd chromosom snps explain phenotyp varianc key snps found haploblock enrich membran associ gene consist hypothes physiolog determin trait result indic promis potenti identifi new allel design next gen wheat cultivar better adapt current futur drought regim
D014908;D055106
T063;T168;T002
36,281,841
challeng water stress index concept thermograph assess arabidopsi transpir water stress may great limit plant function growth stomat closur consequ reduc transpir consid earli sensit plant respons drought salin stress import consequ stomat closur water stress rise leaf temperatur leaf yet leaf fluctuat stomat closur regul sever plant paramet environment factor thermal imag differ stress indic incorpor actual leafcrop temperatur refer temperatur develop previous studi toward normal effect unassoci water stress leaf aim effici water stress assess concept stress indic extens studi model plant arabidopsi thaliana therefor aim studi examin differ indic employ previous studi assess rosett transpir rate e arabidopsi plant grown two differ light environ subject salin salin imposit e gravimetr quantifi thermal imag employ quantifi rosett rosett artifici refer temperatur wet dri rosett sever water stress indic test relat e among microclimat growth condit test rwsi rosett wet dri wet rwsi dri rosett dri wet well linear relat e irrespect light environ sole use either wet dri differ combin rosett return less accur result studi provid evid select combin rosett dri wet util assess e water stress irrespect light environ
D017360;D029681
T116;T002
36,281,840
differenti reset transcriptom genom bias respons orchestr wheat respons phosphat defici phosphorus p essenti macronutri organ phosphat pi defici reduc grain yield qualiti wheat understand wheat respond pi defici global transcript level remain limit revisit avail rna seq transcriptom pi starv wheat root shoot subject pi starvat genom wide transcriptom reset observ pi starvat total gene differenti express root shoot respect chromosom distribut analysi gene triplet differenti express gene deg reveal genom display genom induct bias specif chromosom might key contributor pi limit trigger gene express respons alter multipl metabol pathway pertain secondari metabolit transcript factor pi uptak relat gene evidenc studi provid genom insight dynam landscap transcript chang contribut hexaploid wheat pi starvat outcom studi follow experi potenti assist develop pi effici wheat cultivar
D059467;D014908
T081;T168;T002;T086
36,281,838
phytolith occlud carbon leav dendrocalamus ronganensi influenc drought grow season import carbon c sink phytolith occlud carbon phytoc investig various soil plant system howev effect environment factor ie drought phytolith includ alter deposit plant tissu morpholog variat amount carbon occlud within phytolith less studi studi analyz month variat phytolith product phytoc leav dendrocalamus ronganensi grown karst mountain southwestern china drought year studi thus sought understand effect drought phytolith format morpholog variat carbon sequestr within phytolith plant result show phytolith assemblag phytoc new old leav differ signific vari plant growth stage averag phytoc valu old leav tip leav respect particular phytoc proport elong bulliform flabel stoma phytolith tip leav signific decreas septemb januari follow year drought effect studi suggest phytoc plant vari phytolith morphotyp signific affect plant growth stage hydrolog condit indic improv effici phytolith carbon sequestr plant improv soil water condit requir plant growth
D002244;D055864
T121;T196;T070
36,281,836
populus canescen root suber reaction osmot salt stress limit develop younger root tip region populus valuabl fast grow tree speci common cultiv econom scientif purpos poplar speci sensit drought salt stress thus compar physiolog effect osmot stress peg salt treatment nacl poplar root identifi potenti strategi futur breed genet engin approach investig root anatomi use epifluoresc microscopi chang root suberin composit amount use gas chromatographi transcript reprogram use rna sequenc modif root transport physiolog use pressur chamber poplar root react impos stress condit especi develop younger root tip region remark differ type stress overal increas suberin content surpris small express key suberin biosynthesi gene strong induc signific reduct radial water transport root observ osmot hydrostat hydraul conduct data indic genet enhanc root suber process poplar might promis target convey increas toler especi toxic sodium chlorid
D032107
T002
36,281,827
semant annot experiment method analyt chemistri major obstacl reus integr exist data find data relev given context primari metadata resourc scientif literatur describ experi produc data stimul develop natur languag process method extract inform articl manual annot recent open access public analyt chemistri semant graph focus articl mention mass spectrometri experiment section particular interest topic also within domain sever ontolog control vocabulari result gold standard dataset public avail direct applic valid autom method retriev metadata literatur process also made number observ structur descript experi open access public journal
D012660;D009323
T078;T066
36,281,807
mir juvenil factor plethora form regulatori network influenc time meristem growth later root emerg plant develop throughout live seed becom seedl matur form fruit seed although under mechan drive development phase transit well elucid shoot extent affect root less clear howev root anatomi chang plant matur meristem enlarg radial thicken occur arabidopsi thaliana show overexpress mira gene promot juvenil phase increas densiti root system even graft plant rootstock overexpress genotyp root overexpress mira result lower level plethora protein affect format meristem elong zone cross extra copi plethora partial rescu effect mira overexpress trait affect root architectur includ meristem length rate later root emerg consist plethora also inhibit root tip express anoth mir gene mirc conclud system drive phase chang shoot affect development progress root plethora particip network
D029681;D017360;D035683
T123;T116;T002;T114
36,281,781
inherit adamt mutat associ thrombot thrombocytopen purpura short review updat adamt plasma metalloproteas primari function cleav vwf maintain hemostasi circul adamt close conform blood vessel injuri trigger vwf depend activ open activ form protein adamt multi domain protein domain broad function interact cleav vwf maintain global latenc adamt thrombot thrombocytopen purpura diseas character excess thrombi format microvasculatur diagnosi made adamt activ hereditari form varieti mutat found throughout domain adamt exampl given alongsid detail domain articl adamt mutat inhibit bind cleavag vwf direct indirect reduc secret lead increas size vwf multim platelet recruit molecular character adamt may provid insight mechan ttp aid scientif clinic research
D011697
T047
36,281,778
transit metal ii complex halogen deriv e pyridin ylmethylen hydrazinyl quinazolin structur antioxid activ dna bind dna photocleavag interact albumin silico studi two novel halogen br f quinazolin deriv name e bromopyridin yl methylen hydrazinyl quinazolin l e fluoropyridin yl methylen hydrazinyl quinazolin l synthes character interact seri metal ii ion mn ii ni ii cu ii zn ii cd ii result format six mononuclear complex character spectroscop techniqu singl crystal x ray crystallographi complex bear formula ni l zn l pf cd l h ch oh cu l cl ni l mn l ch oh cl biolog activ compound evalu vitro regard interact calf thymus dna cleavag abil toward supercoil circular pbr plasmid dna absenc presenc irradi various wavelength uva uvb visibl light affin bovin serum albumin abil scaveng diphenyl picrylhydrazyl azinobi ethylbenzothiazolin sulfon acid radic reduc h silico molecular dock calcul employ studi behavior complex toward calf thymus dna bovin serum albumin
D028561;D056831
T104;T196
36,281,776
associ strength e eapp complex correl hpv mediat oncogenesi risk human papillomavirus hpv recogn causat agent cervic cancer women associ anogenit headneck cancer type hpv identifi mani classifi high low risk accord oncogen potenti one protein e evolv overcom oncosuppressor function p target protein degrad via interact human ubiquitin ligas eap studi evalu correl associ strength hpv e type eapp complex hpv oncogenesi risk use molecular simul machin deep learn mldl addit mldl driven predict propos hpv unclassifi oncogen risk type result indic thermodynam play pivot role establish hpv associ cancer highlight need includ viral type hpv relat cancer surveil prevent strategi
D009856;D030361;D052685;D009369
T123;T116;T191;T005;T047
36,281,771
eltrombopag modul phenotyp evolut potenti immunomodulatori role monocytesmacrophag immun thrombocytopenia primari immun thrombocytopenia itp acquir autoimmun hemorrhag diseas loss immun toler play crucial role pathogenesi itp monocyt macrophag play indispens role pathophysiolog hematopoiet malign implic key player platelet destruct approxim adult patient itp exhibit corticosteroid treatment failur becom depend requir novel therapi thrombopoietin tpo receptor agonist tpo ras use clinic manag itp effect howev littl known effect tpo ras monocyt macrophag modul adult itp studi investig phenotyp evolut potenti immunomodulatori role monocytesmacrophag itp patient receiv eltrombopag therapi result show peripher monocyt count posit correl ifn il ratio itp patient moreov numer phenotyp associ gene itp macrophag exhibit divers respons itp macrophag exhibit relat characterist eltrombopag therapi peripher monocyt count ifn il ratio signific decreas itp patient relat characterist itp macrophag partial revers eltrombopag therefor studi reveal eltrombopag restor monocyt dynam associ thth imbal partial revers relat characterist itp macrophag suggest potenti vital role tpo ras regul monocytemacrophag plastic itp
D016553;D013921
T047
36,281,764
multiplex print sensor situ monitor bivalv aquacultur non intrus sensor attach marin speci offer opportun studi impact environment chang behavior well work present thin flexibl sensor tag monitor effect dissolv oxygen salin bivalv gape movement measur rang studi ppm dissolv oxygen sensor g kg salin sensor curvatur strain sensor base electrodeposit semiconduct fiber enabl measur oyster gape sub mm displac multiplex sensor fabric low cost techniqu offer econom conveni platform aquacultur studi
D017756;D049872
T204;T167;T057
36,281,763
compar pharmacist led telehealth care clinic base care uncontrol high blood pressur hyperlink pragmat cluster random trial team approach one effect way lower blood pressur bp uncontrol hypertens differ model organ team base care compar direct
D006973;D017216
T047;T058
36,281,739
abo gene edit convers blood type univers type rh null donor deriv human induc pluripot stem cell limit avail red cell extrem rare blood group phenotyp one global challeng transfus medicin prompt search altern self renew pluripot cell sourc vitro generat red cell rare blood group type one phenotyp rh null lack rh antigen red cell membran repres one rarest blood type world activ blood donor avail worldwid rh null red cell critic transfus immun patient carri phenotyp besid util diagnosi rh alloimmun high preval rh specif suspect patient pregnant woman scenario potenti use human induc pluripot stem cell hipsc deriv rh null red cell also depend abo compat present crisprca mediat abo gene edit strategi convers blood type univers type appli rh null donor deriv hipsc line origin carri blood group work provid paradigmat exampl approach potenti applic hipsc line deriv rare blood donor carri blood type
D057026;D001789
T185;T129;T025
36,281,734
systemat review robot assist cholecystectomi examin qualiti report relat ideal recommend systemat review robot cholecystectomi rc recent innov minim invas gallbladd surgeri ideal idea develop explor assess long term studi framework aim provid safe method evalu innov procedur studi aim understand rc introduc accord ideal guidelin
D002763;D012371
T061;T090
36,281,719
impact intraspecif variat teleost fish aggress domin status stress physiolog domin base social hierarchi common among teleost fish rank anim great affect behaviour physiolog develop outcom fight social domin affect herit factor previous social experi diverg stress cope style demonstr larg number teleost fish display proactiv cope style advantag fight social domin cope style herit compon appear larg determin environment factor especi social experi agonist behaviour control brain social decis make network monoaminerg system play import role modifi activ neuron network review discuss develop domin hierarchi social rank signal visual chemic cue neurobiolog mechan control correl agonist behaviour also consid effect social interact welfar fish rear captiv
D000374;D012930
T055;T054
36,281,716
photothermalnitr oxid synergist anti tumour therapi base mof deriv carbon composit nanoparticl convent organ phototherm convers reagent still face challeng real applic requir carrier vivo transport uncontrol degrad use reduct phototherm convers effici repeat exposur near infrar laser herein uniform zif nanoparticl prepar first carbon etch form porous carbon nanoparticl cnps load donor wrap red blood cell membran novel cnp rbc phototherm agent integr situ imag abil obtain due great phototherm convers effici carbon materi specif releas load conform cnp rbcs show excel tumour cell kill abil base light trigger photothermalga therapi lower dose cnp rbcs
D006979;D009369;D053758
T061;T191;T073
36,281,715
transderm deliveri succin acceler energi dissip brown adipocyt reduc remot fat accumul weight loss increas energi consumpt thermogen adipocyt overcom obes remain challeng herein establish transderm devic base local temporarili control deliveri succin sc tricarboxyl acid cycl metabol intermedi stimul thermogenesi pathway uncoupl protein ucp acceler energi dissip brown adipos tissu bat dorsal interscapular skin initi consumpt fatti acid system metabol sc microneedl patch signific suppress weight gain fat accumul remot organ includ liver peripher white adipos tissu wat high fat diet induc obes mice mrna express level ucp bat brown marker wat signific elev mice treat sc microneedl thus energi dissip bat use ucp mediat thermogenesi acceler transderm deliveri sc may becom potenti effect strategi prevent obes
D052437;D019802
T121;T025;T109
36,281,706
healthcar use year follow bronchiol hospit healthcar util bronchiol hospit incomplet understood aim character readmiss outpati visit within year hospit discharg
D010359;D001988
T058;T047
36,281,693
select mechan muscarin acetylcholin receptor antagon silico investig structur muscarin acetylcholin receptor illustr strike high degre homolog residu among isoform thus lead difficulti achiev subtyp select target receptor caus undesir side effect treat correspond diseas consid urgent need select potenc therapi studi aim reveal select mechan via silico strategi reveal crucial molecular interact hydrogen bond pi cation interact form key residu tyr asn trp respect hydrophob pocket form key residu especi cys besid water around tyr asn replac substitu group form hydrogen bond interact network simul bridg water water around asp whose replac mayb contribut increas bind affin compound may affect inhibitori select among aspect solvent moreov point inhibitor compound posit ioniz group could select bind receptor hydrophob molecul may bind prefer believ current studi would provid basi design subsequ select antagonist
D011976;D014867
T121;T197;T116;T192
36,281,691
optomagnet nanofluid control brain hyperthermia critic studi optomagnet nanofluid omnf colloid dispers nanoparticl nps combin magnet optic properti especi appeal biomedicin sinc use minim invas platform control hyperthermia treatment otherwis difficult access tumor intracrani one one hand magnet nps act heat mediat subject altern magnet field light irradi hand suitabl tailor luminesc nps provid precis remot thermal readout real time combin heat thermometr properti allow principl precis monitor increas temperatur brain tumor therapeut level without caus undesir collater damag work demonstr view oversimplif sinc ignor presenc relev interact magnet fe nanoflow luminesc nanoparticl ag nps result detriment alter physicochem properti magnitud interact depend interparticl distanc surfac properti nanoparticl experi perform mous brain phantom ex vivo reveal omnf induc relev heat altern magnet field fail provid reliabl temperatur read contrast demonstr use luminesc nanofluid contain ag nps act phototherm agent nanothermomet stand better altern thermal monitor hyperthermia treatment brain tumor small anim model
D006979;D001932
T061;T191
36,281,649
docetaxel resist tripl negat breast cancer cell deriv exosom lncrna linc reduc chemosensit breast cancer cell docetaxel via target mir b pbcl axi develop docetaxel txt resist major obstacl tripl negat breast cancer tnbc treatment addit chemoresist cell deriv exosom abl chang chemo respons chemosensit recipi cell via transport lncrnas shown lncrna linc level signific elev breast cancer tissu therefor explor whether linc level increas txt resist tnbc cell deriv exosom addit whether exosom linc deriv txt resist tnbc cell could affect txt sensit txt sensit tnbc cell investig well present studi exosom isol txt resist tnbc cell txt sensit tnbc cell next level linc isol exosom detect rt qpcr found linc express obvious elev txt resist tnbc cell deriv exosom compar txt sensit tnbc cell deriv exosom addit linc could transfer txt resist tnbc cell tnbc cell via exosom moreov txt resist tnbc cell secret exosom linc mark reduc sensit tnbc cell txt via upregul bcl meanwhil downregul linc notabl enhanc sensit txt resist tnbc cell txt downregul bcl addit linc consid cerna spong mir b p therebi elev bcl express collect txt resist tnbc cell deriv exosom linc could decreas chemosensit tnbc cell txt via regul mir b pbcl axi find suggest linc might serv promis target enhanc sensit tnbc cell txt therapi
D064726;D062085;D035683
T123;T191;T114
36,281,647
oxytocin signal posterior hypothalamus prevent hyperphag obes mice decad studi reveal molecular neural circuit base bodi weight homeostasi neural hormon oxytocin oxt receiv attent context produc neuron paraventricular hypothalam nucleus pvh known output center hypothalam regul appetit oxt anorexigen effect shown human studi mediat satieti signal rodent howev function oxt signal physiolog regul appetit remain question whole bodi knockout ko oxt oxt receptor oxtr littl effect food intak herein show acut condit ko cko oxt select adult pvh supraopt nucleus mark increas bodi weight food intak elev level plasma triglycerid leptin intraperiton administr oxt rescu hyperphag phenotyp pvh oxt cko model furthermor show cko oxtr select posterior hypothalam region especi arcuat hypothalam nucleus primari center appetit regul phenocopi hyperphag obes collect data reveal oxt signal arcuat nucleus suppress excess food intak
D010121;D020738
T125;T121;T116
36,281,644
recent advanc electron manipul nanomateri photoelectrochem biosensor photoelectrochem pec biosens promis larg develop techniqu wide appli biolog analysi recent year low background signal high sensit util suitabl pec activ materi establish photoelectr pe convers system select sensit measur achiev help specif biolog recognit element pec biosensor reli chang photocurr depend electron transfer process nanomateri therefor electron manipul pec activ nanomateri crucial pec sens review perspect electron transfer manipul pec activ nanomateri summar principl pec biosensor three part ie generat excit electron pec activ materi introduct specif materi format new electron transfer pathway separ excit electron semiconductor part typic pec biosensor display compar reveal superior differ principl addit current challeng pec biosensor discuss insight given develop pec biosensor futur
D015374;D049329
T059;T073;T075
36,281,643
continu sens ifn hepat endotheli cell shape vascular antimetastat barrier hepat metastas poor prognost factor colorect carcinoma crc new strategi reduc risk liver crc colon high need herein use mous model hepat metastat demonstr continu infus therapeut dose interferon alpha ifn control crc invas act hepat endotheli cell hec mechanist ifn promot develop vascular antimetastat nich character liver sinusoid endotheli cell lsec defenestr extracellular matrix glycocalyx deposit thus strengthen liver vascular barrier impair crc tran sinusoid migrat without requir direct action tumor cell hepat stellat cell hepatocyt liver dendrit cell dcs kupffer cell kcs liver capsular macrophag lcms moreov ifn endow lsec effici cross prime potenti along earli intravascular tumor burden reduct support generat antitumor cd cell ultim led establish protect long term memori cell respons find provid rational use continu ifn therapi periop set reduc crc metastat spread liver
D016898;D015179
T129;T121;T191;T116
36,281,640
health profil older nurs home resid suicid ideat latent class analysi identifi health profil older nurs home resid without admiss self report suicid ideat si examin associ identifi profil self report si day
D000073496;D060825
T033;T184;T046;T048
36,281,636
neural defens circuit underli help threat human empathi other distress long consid drive forc help howev decid help other danger one must consid distress also risk oneself wherea role self defens help overlook human research studi anim indic defens respons necessari protect conspecif pre regist studi n demonstr human defens neural circuit implic help other threat particip underw fmri scan decid whether help anoth particip avoid avers electr shock risk also shock found higher engag neural circuit coordin fast escap self direct danger includ insula pag acc facilit decis help other import use represent similar analysi found strength amygdala insula uniqu repres threat oneself distress predict help find indic human mammal defens mechan play greater role help behavior previous understood
D005239;D000679
T023;T041
36,281,634
investig valid edinburgh social cognit test escot acquir brain injuri abi social cognit frequent impair follow acquir brain injuri abi often overlook clinic assess valid appropri measur social cognit abil abi patient current studi examin valid edinburgh social cognit test escot baksh et al measur social cognit follow abi
D000083282;D001930
T037;T054
36,281,620
patient epstein barr virus posit esophagogastr junction cancer splenic metastasi underw metastasectomi follow immun checkpoint therapi recurr gastric cancer gc splenic metastasi show poor prognosi treatment strategi remain unclear recent studi identifi consider prognost effect metastasectomi gc follow intens chemotherapi success treat patient epstein barr virus posit esophagogastr junction cancer splenic metastasi underw metastasectomi obtain patholog complet respons follow immun checkpoint therapi long term surviv review literatur discuss clinic signific treatment strategi
D059146;D020031;D013160;D013274;D016609
T061;T047;T191
36,281,619
success postop recurr treatment malign melanoma esophagus anti pd anti ctla combin therapi case report malign melanoma esophagus extrem rare poor prognosi recent efficaci anti pd antibodi alon combin anti ctla antibodi demonstr patient recurr unresect mucos malign melanoma report describ case postop recurr malign melanoma esophagus treat use combin anti pd anti ctla antibodi result long term surviv patient year old man develop liver metastasi left mediastin lymph node recurr year month resect stage malign melanoma middl thorac esophagus cours nivolumab ipilimumab combin therapi mainten therapi nivolumab alon continu patient surviv month diseas cours neutrophillymphocyt ratio nlr lymphocytemonocyt ratio lmr show ed trend reflect tumor status addit sil r ly monitor new biomark seem use diseas assess
D000077594;D008545
T129;T121;T191;T116
36,281,618
case curat surgeri local advanc small bowel gist imatinib therapi accord risk classif recurr standard treatment gastrointestin stromal tumor gist complet surgic resect postop adjuv therapi imatinib howev use neoadjuv therapi unclear report case giant gist pelvi suspect bladder infiltr radic resect underw preoper imatinib therapi year old man visit clinic abdomin pain fever frequent urin abdomin mass determin patient refer hospit detail examin treatment contrast enhanc ct reveal cm diamet irregular mass lower navel pelvi bladder boundari partial unclear transrect biopsi perform use endoscop ultrasonographi accord fletcher classif high risk gist diagnos preoper imatinib therapi mgday administ month surgeri perform tumor strong adher bladder invas observ partial small intestin resect perform surgic margin negat without capsul damag day postop imatinib therapi resum year postop cours well without recurr
D046152;D000970;D007414
T121;T191;T109
36,281,617
case serous retin detach encorafenib binimetinib cetuximab treatment braf mutant colorect cancer patient year old man chief complaint abdomin pain perform laparoscop left hemicolectomi colon descend colon cancer ileus stent postop patholog ptanm pstage b year postop liver metastas lymph node metastasi found resect chemotherapi initi multipl lung metastas genet test posit braf mutat patient receiv mfolfoxiri plus bevacizumab therapi cours fu plus lv plus bevacizumab cours patient brain infarct lung metastasi reincreas chemotherapi chang encorafenib plus binimetinib plus cetuximab day visual impair observ serous retin detach ctcae grade diagnos day symptom improv one step dose reduct resum day treatment serous retin detach recur treatment discontinu day treatment symptom improv anoth dose reduct perform treatment resum sinc subject mek inhibitor induc ocular symptom often minor conduct interview earli ophthalmolog diagnosi recommend
D012163;D015179
T047;T191
36,281,616
case pembrolizumab therapi mark effect advanc recurr colorect cancer report case pembrolizumab therapi fourth line therapi colorect cancer multipl lymph node recurr high frequenc microsatellit instabl msi high patient year old woman diagnos ascend colon cancer ptanbm stage c underw laparoscop right hemicolectomi dissect function end end anastomosi insert self expand metal stent postop adjuv chemotherapi perform patient follow postop year month lymph node recurr indic folfox plus panitumumab therapi introduc folfiri plus ramucirumab therapi ftdtpi introduc second line third line treatment respect howev recurr lymph node exacerb show treatment resist lymph node biopsi confirm msi high pembrolizumab therapi initi fourth line treatment therapi lymph node reduc mark patient remain undergo chemotherapi without advers event
D008197;D015179
T061;T191
36,281,615
case rectal cancer brain skin metastasi long term surviv manag multidisciplinari therapi year old man present metastat brain tumor right pariet lobe observ mri scan lower gastrointestin endoscopi reveal tumor locat rectum diagnos stage b rectal cancer ctanbmb bra skn prior stereotact radiotherapi brain metastas patient underw rectal amput dissect manag primari tumor postop cours unev discharg hospit day postop display partial respons capecitabin plus l ohp therapi chemotherapi termin due develop renal dysfunct follow elev tumor marker enlarg left mediastin lymph node fdg accumul pet ct observ despit initi uftuzel therapi patient judg progress diseas patient administ fu plus l lv plus cpt howev later discontinu due develop hyperammonemia patient place follow observ due decreas tumor marker disappear enlarg lymph node still aliv seven year initi diagnosi report case patient rectal cancer metastas brain skin success manag multidisciplinari therapi relev literatur discuss also includ
D000072078;D012004
T060;T191
36,281,614
case braf mutant colorect cancer treat effect encorafenib binimetinib cetuximab tripl therapi year old woman diagnos left side transvers colon cancer invad pancreat tail multipl liver metastas periton dissemin preoper diagnosi ctb si namc h p cstage c harbor braf mutat transvers colostomi perform folfoxiri plus bevacizumab bev administ chemotherapi cycl primari tumor metastat lesion show partial respons cea elev fu plus lv plus bev mainten therapi chang regimen switch encorafenib plus binimetinib plus cetuximab second line chemotherapi patient develop dermat around colostomi start second line chemotherapi result tempor cetuximab monotherapi improv dermat patient resum encorafenib plus binimetinib improv liver metastas eight month start second line patient administ tripl therapi stabl diseas status
D015179;D008113;D003872
T047;T191
36,281,613
effect bridg surgeri bts malign colorect stenosi nutrit immunolog status studi aim clarifi effect bridg surgeri bts malign colorect stenosi nutrit immunolog status
D007415;D015179
T047;T191
36,281,612
monitor blood marker predict nivolumab effect esophag carcinoma investig whether monitor neutrophil lymphocyt ratio nlr serum interleukin receptor lymphocyt ratio sil r ly could predict nivolumab nivo effect treat patient esophag cancer progress free surviv pfs day overal surviv os day one patient chemotherapi intoler switch nivo achiev cr other pd four patient ira correl treatment respons patient pretreat low sil r ly nlr increas treatment signific longer os better prognosi therefor host paramet nlr sil r lymphocyt count signific real time monitor nivo therapi esophag carcinoma
D002289;D008175;D004938
T191
36,281,611
long term prognosi patient biliari tract cancer undergo pancreaticoduodenectomi divid patient biliari tract cancer underw pancreaticoduodenectomi pd hospit year recurr free recurr group investig prognost factor addit investig efficaci adjuv chemotherapi patient without lymph node ln metastasi signific differ two group patient characterist periop factor howev patient ln metastasi tend higher recurr rate patient without ln metastasi median overal surviv os signific differ patient receiv receiv adjuv chemotherapi patient ln metastasi although signific differ p os patient receiv adjuv therapi time patient month month respect patient biliari tract cancer underw pd posit ln metastasi may poor prognost factor adjuv therapi may possibl improv prognosi
D016577;D001661
T061;T191
36,281,610
analysi short term outcom nutrit assess elder gastric cancer surgeri case analyz short term outcom nutrit assess gastric cancer surgeri patient underw exercis intervent gastrectomi
D013274;D010535
T060;T191;T061
36,281,609
express cgas sting pathway dmmrmsi h colorect cancer defici mismatch repair dmmr microsatellit instabl msi h colorect cancer crc high immunogen although cyclic gmp amp synthas cgas stimul interferon gene sting pathway activ consider contribut high number cd tumor infiltr lymphocyt til role dmmrmsi h crc larg unknown studi investig associ cgas sting express cd til crc data analysi use tcga dataset crc cohort show cgas sting cd gene express level signific higher msi group immunohistochemistri examin resect clinic crc sampl show cgas sting express tumor cell high msi crc cd til also signific infiltr msi group moreov signific cd til infiltr observ crc high cgas sting express level result suggest dmmrmsi h crc maintain high cgas sting express may contribut abund cd til
D053842;D015179
T049;T191
36,281,608
telomeras specif oncolyt adenovirus express p gene stimul cd memori cell pancreat cancer pancreat cancer poor prognosi despit various develop multimod treatment strategi current neoadjuv chemotherapi immunotherapi attract substanti attent effect treatment strategi howev amplifi immun respons exist treatment difficult develop telomeras specif oncolyt adenovirus oa includ obp current test clinic trial combin anti pd antibodi p arm obp variant obp oa immun modul function induc cd cell tumor releas immunogen cell death marker extracellular adenosin triphosph investig effect obp pancreat cancer treatment focus influenc cd memori cell
D050130;D010190;D019098
T061;T191;T126;T116
36,281,607
case unilater interstiti lung diseas patient treat oxaliplatin fluorouracil leucovorin respiratori symptom rare report side effect oxaliplatin fluorouracil leucovorin folfox therapi report case patient folfox induc unilater interstiti pneumonia patient year old man underw ileocec resect cecum cancer folfox regimen start adjuv chemotherapi administr cours visit hospit fever dyspnea anorexia diagnos folfox induc unilater interstiti pneumonia blood test chest radiograph comput tomographi bronchoscopi treatment start mg prednisolon dosag gradual decreas patient respond well treatment discharg hospit without complic th day admiss
D017563;D015179
T047;T191
36,281,606
multidisciplinari treatment postop recurr patient report long term survivor present long term survivor receiv multidisciplinari treatment postop recurr year old femal clinic diagnos primari lung cancer underw right lower lobectomi middl lobe wedg resect lymph node dissect nda patholog diagnos primari pulmonari papillari adenocarcinoma ptnm stage b posit sensit egfr mutat lr patient given uft postop adjuv chemotherapi year follow multipl pulmonari metastas occur postop month gefitinib administ first line treatment result complet respons month stereotact radiotherapi administ brain metastas multipl pulmonari metastas treat cisplatin plus pemetrex carboplatin plus pemetrex pd advers event occur therefor pemetrex monotherapi administ fourth line treatment month afatinib nivolumab docetaxel osimertinib pembrolizumab atezolizumab th line treatment administ pd new lesion final best support care administ die postop month post recurr month
D002289;D008175;D000077192
T191
36,281,605
long term complet respons follow chemotherapi advanc gastric cancer elder patient year old man diagnos posit advanc gastric cancer ctnm lym b cstage b refer anemia lesion deem unresect first line chemotherapi initi use cisplatin cddp trastuzumab mab cours chemotherapi patient develop febril neutropenia grade point lesion show partial respons pr chemotherapi continu use oral singl agent month monotherapi para aortic lymph node metastas show complet respons cr monotherapi continu without major advers event year patient present aliv well year obtain clinic cr may suggest safe effect treatment unresect advanc gastric cancer elder patient
D013274
T191
36,281,604
case neuroendocrin carcinoma stomach treat tas year old woman underw distal gastrectomi lymph node dissect cholecystectomi follow roux en reconstruct stage c gastric neuroendocrin cell carcinoma januari juli year abdomin comput tomographi scan reveal liver metastasi segment treatment recurr sp therapi cisplatin ramucirumab plus week paclitaxel therapi nivolumab administ order tas start fourth line agent multipl liver metastas para aortic lymph node metastas cancer periton although grade anemia grade oral mucos general fatigu observ treatment liver metastas para aortic lymph node metastas show improv three cours patient abl continu cours year die year month first administr tas tas effect immun checkpoint inhibitor late treatment gastric cancer nec appropri time switch drug therapi may import futur report favor therapeut effect tas immun checkpoint inhibitor treatment along review literatur
D013274;D018278;D008113
T191
36,281,603
case perfor unresect esophag cancer nivolumab therapi year old man visit hospit complain dysphagia diagnos unresect esophag cancer multipl lung metastas cstage b gastric cancer l gre tnm cstage esophag lesion lung metastat lesion show shrinkag initi fu cddp fp therapi grew therefor therapi chang nivolumab therapi three cours nivolumab therapi patient visit hospit high fever admit emerg patient diagnosi esophag perfor mediastin abscess ct guid drainag perform self expand metal stent sem place discharg st day hospit nivolumab therapi resum report first case esophag perfor immunotherapi nivolumab therapi esophag cancer
D004939;D004938
T046;T191
36,281,602
clinic outcom microsatellit instabl high patient treat pembrolizumab genet counsel prospect studi demonstr efficaci pembrolizumab patient previous treat unresect metastat microsatellit instabl high msi h cancer pembrolizumab cover japanes health insur system sinc decemb frequenc msi h patient low approxim addit patient msi h cancer diagnos lynch syndrom present studi retrospect investig patient receiv msi test kitasato univers hospit april june also investig therapeut effect pembrolizumab msi h cancer patient receiv genet counsel lynch syndrom result identifi patient underw msi test msi h therapeut outcom pembrolizumab patient follow complet respons partial respons progress diseas posit outcom rate msi h treatment institut compar previous report high respons rate pembrolizumab confirm present studi four patient receiv genet counsel genet clinic patient underw genet test lynch syndrom deleteri variant lynch syndrom detect genet test
D053842;D003123
T049;T047;T191
36,281,601
incid immun relat advers event switch convent regimen nivolumab pembrolizumab extend dose interv regimen new nivolumab pembrolizumab monotherapi regimen doubl convent dose longer dose interv new regimen approv report incid immun relat advers event ira earli phase switch convent regimen new regimen ogaki municip hospit thirti seven patient switch new regimen octob februari switch nivolumab pembrolizumab two patient treat nivolumab develop ira one patient develop grade coliti day follow switch new regimen treatment discontinu patient develop grade adren insuffici day hospit ira observ pembrolizumab treatment result suggest high sever grade ira may occur earli switch new regimen
D000077594;D000074322
T129;T121;T116
36,281,600
use nutrit evalu adjuv chemotherapi colorect cancer older patient clarifi use onodera prognost nutrit index opni adjuv chemotherapi ac older patient colorect cancer
D015596;D015179
T060;T081;T170;T191
36,281,599
factor affect adher adjuv endocrin therapi japanes patient breast cancer observ studi purpos studi investig adher adjuv endocrin therapi et factor affect demotiv motiv continu adjuv et patient hormon receptor posit breast cancer japan onlin survey conduct june juli investig treatment effect side effect concern side effect demotiv conveni hospit visit treatment durat concern recurrenceprogress treatment cost support healthcar profession support famili patient associ peer motiv accord respons patient common factor affect demotiv continu adjuv et burden side effect common factor affect motiv continu adjuv et concern recurrenceprogress continu relief burden side effect earli stage treatment mental support concern recurrenceprogress well explain promot risk benefit continu treatment consid lead motiv continu adjuv et fig summari survey
D001943
T191
36,281,593
ntrk gene fusion treatment ntrk fusion posit solid cancer neurotroph tyrosin receptor kinas ntrk gene variant report varieti cancer type preval ntrk gene variant less mani type solid cancer highest ntrk gene fusion frequenc found secretari breast carcinoma infantil fibrosarcoma sever method detect ntrk gene variant includ rt pcr comprehens genom profil two ntrk inhibitor entrectinib larotrectinib approv ntrk gene fusion posit solid cancer japan ntrk inhibitor provid durabl respons durat respons may limit acquir resist next generat trk inhibitor expect overcom acquir resist
D020917;D009369
T191;T126;T116;T192
36,281,592
cancer therapi target fusion gene lung cancer therapeut landscap lung cancer undergon dramat shift due better understand diseas biolog identif oncogen driver alter consequ new classif paradigm non small cell lung cancer character molecular defin subset make therapeut landscap increas complex driver gene mutat found approxim japanes non squamous non small cell lung cancer among gene mutat molecular target therapi develop includ egfr mutat alk fusion gene ros fusion gene braf mutat met exon skip mutat kras gc mutat ret fusion gene ntrk fusion gene limit fusion gene june crizotinib ceritinib alectinib brigatinib lorlatinib approv alk fusion gene crizotinib entrectinib ros fusion gene selpercatinib ret fusion gene entrectinib larotrectinib ntrk fusion gene approv japan articl summar therapeut develop fusion gene mutat well therapeut outcom advers event approv drug
D008175;D002289
T191
36,281,591
cancer therapi target fusion gene fgfr fusion gene biliari tract cancer gemcitabin plus cisplatin mainstay first line chemotherapi unresect biliari tract cancer standard care second line establish recent year genet abnorm biliari tract cancer identifi therapeut develop target genet abnorm promot march base result fight trial pemigatinib approv treatment fgfr fusion gene posit biliari tract cancer pemigatinib attract attent new treatment option unresect biliari tract cancer clinic trial data inform cancer therapi target fgfr fusion gene present
D001661;D002945
T121;T197;T191
36,281,590
evolut treatment chronic myelogen leukemia chronic myelogen leukemia cml myeloprolif neoplasm caus reciproc transloc q q find constitut tyrosin kinas activ bcr abl fusion protein produc fuse abl bcr gene involv pathogenesi cml led develop drug target bcr abl fusion protein imatinib first generat tyrosin kinas inhibitor tki introduc treatment cml dramat chang cml therapi advent imatinib diseas progress larg prevent prognosi cml patient mark improv allow substanti proport patient remain chronic phase extend period time tki era longer primari diseas defin long term prognosi cml patient rather comorbid cml advers event ae includ cardiovascular event manag avoid ae associ long term tki use becom increas import recent year treatment free remiss tfr becom new therapeut goal mani report shown patient achiev deep molecular respons tkis maintain long term tfr without relaps tki discontinu
D015464
T191
36,281,589
fusion gene cancer toward treatment pan cancer perspect recent year genet test use next generat sequenc becom widespread field cancer drug therapi treatment base individu genet disord routin use drug develop underway target various fusion gene among detect genet disord howev function signific detect fusion gene unknown necessari understand biolog characterist elucid function develop person medicin review molecular biolog detect treatment cancer fusion gene pan cancer perspect
D009369;D000970
T121;T191;T109
36,281,588
patient public involv cancer clinic research involv patient public research essenti clinic research cancer treatment recent year patient public involv ppi requir medic research process paper summar practic consider exampl ppi process refer patient public involv ppi guidebook japan agenc medic research develop ame process consist introduct ppi recruit ppi particip conflict interest manag reward ppi particip confidenti ppi particip report result feedback difficult provid standard procedur ppi activ vari among research project recommend implement ppi activ research project util actual case exist inform sourc
D010358;D009369
T081;T058;T191;T080
36,281,583
origin doubl band featur ethylen cc stretch mode retin chromophor heliorhodopsin photoreceptor protein play critic role light util energi convers environment sens rhodopsin prototyp photoreceptor protein contain retin group function light recept site essenti character structur retin chromophor chromophor structur along retin protein interact regul wavelength light absorb reson raman spectroscopi power tool character chromophor structur protein reson raman spectra heliorhodopsin recent discov rhodopsin famili previous report exhibit two intens ethylen cc stretch band never observ type rhodopsin show doubl band featur ethylen cc stretch mode due structur inhomogen rather retin polyen chain linear structur contrast bent tran chromophor type rhodopsin linear structur chromophor result weak atom contact methyl group nearbi trp side chain slow thermal reisomer photocycl possibl deceler reisomer increas lifetim signal intermedi photosensori function
D012243;D025604
T123;T116
36,281,568
chang util lumbosacr epidur inject descript epidemiolog studi
D006278;D000767
T089;T064;T061
36,281,559
ultrasensit catechin electrochem sensor base uniform order mesopor carbon hollow sphere mchss advanc carbon base conduct materi catechin one flavonoid antioxid activ attract great interest rapid accur detect catechin great signific herein ultrasensit catechin electrochem sensor base uniform order mesopor carbon hollow sphere mchss advanc carbon base conduct materi modifi glass carbon electrod construct mchss synthes pyrolysi use nitrogen protect templat remov method exhibit excel electrochem detect catechin owe high conduct uniform small sphere larg specif surfac area hollow structur optim condit detect catechin mchssgce show wider linear rang nm lower detect limit lod nm sn furthermor electrochem reaction site redox mechan catechin reveal electrochem behavior densiti flood theori moreov sensor construct exhibit good accuraci stabil detect catechin actual sampl detect
D002244;D002392
T121;T196;T109
36,281,553
ectop pancrea wall necrosi mimick malign submucos gastric tumor ectop pancrea rare transform malign symptom vari patient patient common observ site ectop pancrea antrum stomach year old male patient sever abdomin pain underw ct cm size well defin exophyt huge mass heterogen densiti locat stomach distal antrum duodenum malign submucos tumor suspect exophyt dirti huge mass initi surgeri consid confirm histolog evalu month abdomin pain disappear follow mri scan show decreas size contain necrot compon insid confirm parenchym tissu pancrea patholog eus guid fine needl aspir eus fna normal pancreat acinar cell smooth muscl fragment squamous cyst neutrophil abscess wall necrosi occur complic acut pancreat parenchym tissu surround tissu complic ectop pancreat occur case abdomin pain due ectop pancrea lead format giant abscess report rare case diagnosi biopsi import malign submucos tumor suspect addit import determin clinic featur examin find eus ct mri chang accord follow period paper report case ectop pancrea result necrot tissu wall necrosi abdomin pain spontan improv
D013274;D010195;D010190
T047;T191;T046
36,281,552
gastric cd negat extranod natur killert cell lymphoma case report extranod natur killer nk cell lymphoma nasal type enktcl nt common subtyp epstein barr virus associ nkt cell lymphoma enktcl nt occur infrequ gastrointestin tract particular report enktcl nt aris stomach extrem rare sever cluster differenti cds use recogn nk cell cell tumor cell nkt cell lymphoma among cd antigen consid sensit marker enktcl nt express almost case enktcl nt thus develop cd negat enktcl nt high atyp paper report case young asian femal present gastric ulcer bleed patient histolog diagnos enktcl nt tumor cell cd observ wherea monoclon cell receptor gamma gene rearrang detect tumor cell patient schedul system chemotherapi six time achiev complet remiss peripher blood hematopoiet stem cell transplant perform later
D020031;D016399
T047;T191
36,281,551
small bowel obstruct caus spontan transoment hernia case report intern hernia protrus viscer content defect mesenteri peritoneum small bowel obstruct common clinic present intern hernia account intestin obstruct transoment hernia rare type intern hernia intern hernia non specif symptom make preoper diagnosi difficult strangul frequent postop mortal rate high therefor earli diagnosi manag crucial report case year old femal present small bowel obstruct suspect incarcer intern hernia abdomen pelvi ct spontan transoment hernia confirm emerg laparotomi
D007415;D046449
T047;T190
36,281,550
efficaci safeti endoscop stent crohn diseas relat strictur systemat review meta analysi endoscop stent evolv treatment symptomat crohn strictur sever case seri small studi report efficaci futur studi design base systemat review evalu efficaci henc meta analysi conduct assess critic role stent manag intestin strictur associ crohn diseas cd
D003424
T047
36,281,549
clinic featur hepat c virus relat acut chronic liver failur korean popul acut chronic liver failur aclf wide recogn concept acut decompens ad patient cirrhosi result organ failur high short term mortal hand studi reflect various etiolog cirrhosi avail studi examin clinic featur patient hepat c virus hcv relat aclf
D065290;D006526
T047